Hepatocellular Carcinoma Clinical Trial
— DUET-3Official title:
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors
Verified date | February 2024 |
Source | Xencor, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.
Status | Active, not recruiting |
Enrollment | 300 |
Est. completion date | September 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Subjects in Part A (dose escalation) must have a diagnosis of any of the following: Histologically or cytologically confirmed advanced solid tumors, including the following: 1. Melanoma (excluding uveal melanoma) 2. Cervical carcinoma 3. Pancreatic carcinoma 4. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative 5. Hepatocellular carcinoma 6. Urothelial carcinoma 7. Squamous cell carcinoma of the head and neck 8. Nasopharyngeal carcinoma 9. Renal cell carcinoma 10. Colorectal carcinoma 11. Endometrial carcinoma 12. NSCLC 13. Small cell lung cancer 14. Gastric or gastroesophageal junction adenocarcinoma 15. Sarcoma 2. Subjects in Part B (expansion) must have a diagnosis of any of the following: Histologically or cytologically confirmed advanced solid tumors of the following types: 1. Non-squamous NSCLC 2. Melanoma 3. HNSCC, including NPC 4. CRC 5. UPS, including other select high grade STS, such as MFS 6. ccRCC Prior to enrolling into Part B (expansion), subjects should have received disease-specific standard therapy as indicated for: 1. Non-squamous NSCLC 2. Melanoma 3. HNSCC, including NPC 4. CRC 5. UPS, including other select high-grade STS such as MFS 6. RCC, clear cell histology (ccRCC) 3. Subjects in Part C (expansion)must have a diagnosis of MSS or proficient mismatch repair CRC with the following: 1. cancer must have progressed after treatment with standard/approved therapies or have no appropriate available therapies 2. subjects will have life expectancy greater than 3 months 4. All subjects' cancer must have progressed after treatment with standard/approved therapies or have no appropriate available therapies. 5. Subjects must have measurable disease by RECIST 1.1. 6. All subjects must have adequate archival tumor sample (slides or archival FFPE block[s] containing tumor. 7. All subjects in Part B (dose expansion) must have a tumor lesion that can be biopsied at acceptable risk (in the judgment of the Investigator) and must agree to both a fresh biopsy during screening and a second biopsy following treatment. 8. Subjects have an ECOG performance status of 0-1. Exclusion Criteria: 1. Currently receiving other anticancer therapies 2. Prior treatment with an investigational anti-ICOS therapy 3. Treatment with any PDL1 or PDL2-directed therapy within 4 weeks of the start of study drug 4. Treatment with nivolumab within 4 weeks of the start of study drug 5. Treatment with pembrolizumab within 24 weeks of start of study drug for Cohorts 1A - 10A 6. Treatment with any other anticancer therapy within 2 weeks of the start of study drug (ie, other immunotherapy, chemotherapy, radiation therapy, etc.) 7. A life-threatening (Grade 4) irAE related to prior immunotherapy 8. Failure to recover from any irAE from prior cancer therapy to Grade = 1, except for endocrinopathies that are on stable hormone replacement doses 9. Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to Grade = 2 10. Known active central nervous system involvement by malignant disease. Subjects with previously treated brain metastases may participate provided they are radiologically stable, ie, are without evidence of progression for at least 4 weeks by repeat imaging and are clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment. 11. Active known or suspected autoimmune disease 12. Receipt of an organ allograft 13. History or evidence of any other clinically unstable/uncontrolled disorder, condition, or disease (including, but not limited to, cardiopulmonary, renal, metabolic, hematologic or psychiatric) other than their primary malignancy, that in the opinion of the Investigator would pose a risk to patient safety or interfere with study evaluations, procedures, or completion 14. Treatment with antibiotics within 14 days prior to first dose of study drug 15. Receipt of a live-virus vaccine within 30 days prior to first dose of study drug (seasonal flu vaccines that do not contain live virus are permitted). 16. Treatment with ipilimumab within 4 weeks of the start of study drug |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
United States | Emory University | Atlanta | Georgia |
United States | University of Colorado Hospital - Anschutz Cancer Pavilion | Aurora | Colorado |
United States | Emily Couric Clinical Cancer Center | Charlottesville | Virginia |
United States | Mary Crowley Cancer Research - Medical City | Dallas | Texas |
United States | Sarah Cannon Research Institute at HealthONE | Denver | Colorado |
United States | Duke Cancer Institute | Durham | North Carolina |
United States | The University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | University of Iowa Hospitals and Clinics | Iowa City | Iowa |
United States | Columbia University Medical Center | New York | New York |
United States | University of Pennsylvania Abramson Cancer Center | Philadelphia | Pennsylvania |
United States | UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania |
United States | Providence Portland Medical Center | Portland | Oregon |
United States | Washington University School of Medicine Siteman Cancer Center | Saint Louis | Missouri |
United States | University of Utah, Huntsman Cancer Institute | Salt Lake City | Utah |
United States | UC San Diego Moores Cancer Center | San Diego | California |
United States | Florida Cancer Specialists | Sarasota | Florida |
United States | Seattle Cancer Care Alliance | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Xencor, Inc. | ICON plc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Treatment-related adverse events as assessed by CTCAE v4.03 | Safety and tolerability | 56 Days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |